Marquee investor Ashish Kacholia is known for having a knack to pick lesser-known mid & smallcap stocks that tend to outperform the market has recently added Venus Remedies in his portfolio. The stock has rallied 200% since the beginning of 2021 from Rs 165 on January 1 to the current price of Rs 495 as they were locked in an upper circuit of 20%.
According to the shareholding pattern of Venus Remedies for the July to September 2021 quarter filled by the company on BSE shows that Ashish Kacholia holds 1.50 lakh shares or a 1.12% stake in the company. For the quarter ended June 2021, his name didn’t appear in the list of shareholders that held more than a per cent stake in the company.
The multi-bagger stock has increased from Rs 130 to Rs 495 level in the last year. There has been an increase of about 280% in this period. Investors who would have invested Rs 1 lakh in the stock of this pharma company a year ago, have seen their investment grow to Rs 3.80 lakhs.
In June this year, Venus Remedies won a 10-year-long battle with French company SCR Pharmatop over the patent rights to the drug Paracetamol. The Indian pharmaceutical company had launched a legal battle to clear any patent rights hurdle in manufacturing paracetamol solutions in the country.
Venus Remedies had opposed the patent in 2011. After this, the patent was withdrawn in 2018. However, SCR Pharmatop later moved to the Delhi High Court and the Intellectual Property Appellate Board (IPAB). Venus Remedies, based in Baddi, Himachal Pradesh, is one of the world’s leading Paracetamol Injection manufacturers with a presence in over 70 countries.
Meanwhile, Ashish Kacholia has also bought a stake in some other multi-bagger stocks like Gateway Distriparks and Somany Home Innovation. These shares have also given multi-bagger returns to their shareholders in 2021. Shares of Gateway Distriparks have gained nearly 130% year-on-year, while Somani Home Innovation share price has risen close to 179% in 2021.
Download Money9 App for the latest updates on Personal Finance.